Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

Cancer

Volumn 112, Issue 12, 2008, Pages 2710-2719

  Vermorken, Jan B ^a   Herbst, Roy S ^b   Leon, Xavier ^c   Amellal, Nadia ^d   Baselga, Jose ^e  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Merck KGaA France   (France)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Carboplatin; Cetuximab; Cisplatin; Epidermal growth factor receptor; Head and neck cancer; Second line; Squamous cell carcinoma of the head and neck

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; GEMCITABINE; METHOTREXATE; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALAISE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; VOMITING; COMPARATIVE STUDY; DRUG RESISTANCE; HEAD AND NECK TUMOR; MIDDLE AGED; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 46049084643     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23442     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Iro H, Waldfahrer F. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer. 1998;83:2201-2207.
3. Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer. 2000;36:1032-1037.
4. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245-1251.
5. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT, Hellman SA, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology, 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:797-860.
6. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) who are progressing while on a platinum-based palliative chemotherapy [abstract]. Proc Am Soc Oncol. 2003;22:502. Abstract 2022.
7. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17:418-424.
8. Numico G, Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol. 2002; 13:331-333.
9. Iop A, Cartel G, Isaia A. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. Ann Oncol. 1998;9:225-227.
10. Moroni M, Giannetta L, Gelosa G, et al. Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen: a phase II study. J Chemother. 2003;15:394-399.
11. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol. 2003;30:3-14.
12. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29:27-36.
13. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-7356.
14. Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Hansen GN, Bretlau P. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch Otorhinolaryngol. 1992; 249:243-247.
15. Grandis RJ, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90:799-801.
16. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995;1:1311-1318.
17. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997;3:2703-2707.
18. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 725 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993;53:4322-4328.
19. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Russie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311.
20. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994;269:27595-27602.
21. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19: 3234-3243.
22. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
23. Burtness BA, Goldwasser MA, Flood W, Mattar BI, Forastiere A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/ recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 2005;23:8646-8654.
24. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866-2872.
25. Vermorken JB, Mesia R, Vega E, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized phase III (EXTREME) study [abstract]. Proc Am Soc Clin Oncol. 2007;25:670s. Abstract 16516.
26. Trigo J, Hitt R, Koralewski P, et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study [abstract]. J Clin Oncol. 2004;22(14S). Abstract 5502.
27. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2152-2155.
28. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5577.
29. Baselga J, Trigo JM, Bourhis J, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract]. Proc Am Soc Clin Oncol. 2002;21. Abstract 900.
30. Herbst RS, Arquette M, Shin DM, et al. Epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck: a phase II, multicenter study. J Clin Oncol. 2005; 23:5578-5587.
31. Kies MS, Arquette MA, Nabell L, et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract]. Proc Am Soc Clin Oncol. 2002; 21. Abstract 925.
32. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
33. Vermorken JB, Bourhis J, Trigo J, et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies [abstract]. J Clin Oncol. 2005;23. Abstract 5505.
34. Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005;3:599-606.
35. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005; 16:1425-1433.
36. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Proc Am Soc Clin Oncol. 2003;22. Abstract 817.
37. Merlano M, Grimaldi A, Bonelli L, Tatarek R, Rosso R. Failure of second-line therapy to modify survival in relapsed squamous cell carcinoma of the head and neck. Tumori. 1985;71:367-370.
38. Keldsen N. Cisplatin as second line chemotherapy in advanced or recurrent squamous cell carcinoma of head and neck region. Acta Oncol. 1987;26:357-359.
39. Gebbia V, Valenza R, Testa A, et al. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/ or metastatic squamous cell carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec. 1994;56:279-282.
40. Porta C, Brugnatelli S, Patruno E, et al. Single-agent vinorelbine (VRB) as second-line treatment for advanced or recurrent squamous-cell carcinoma of the head and neck (SCCHN) [abstract]. Proc Am Soc Clin Oncol. 2001;22. Abstract 2537.
41. Gustafson NF, Saltz L, Cunningham D, Lenz H, Humphrey R, Adegbile IA. Safety profile of cetuximab in patients with metastatic colorectal cancer [abstract]. Presented at the 2004 ASCO Gastrointestinal Cancers Symposium, San Francisco, California, January 22-24, 2004. Abstract 237.